Table 2.
All subjects (n = 234) | |
---|---|
Demographics, median (IQR) or n (%) | |
Age in years | 11.6 (9.8–13.7) |
Sex, male | 169 (72.2) |
Race, Caucasian | 194 (82.9) |
Family history of HLA-B27-associated disease | 36 (15.4) |
Clinical characteristics, median (IQR) or n (%) | |
HLA-B27 positivity | 135 (59.2) |
Active joint count | 2 (1–4) |
Tender entheses count | 2 (1–4) |
MRI-defined sacroiliitis (n = 45 with imaging) | 25 (55.6) |
Polyarticular onset | 52 (22.2) |
ANA-positive | 49 (23.4) |
CRP, abnormal/elevated | 39 (26.9) |
ESR, abnormal/elevated | 93 (45.8) |
Patient-/physician-reported outcomes, median (IQR) | |
Physician global disease activity assessment (0–10) | 2.5 (2–4) |
Juvenile Spondyloarthritis Disease Activity Index (JSpADA) (0–8) | 3 (2.5–4) |
Juvenile Arthritis Disease Activity Score (cJADAS), excluding ESR (0–30) | 9 (5–14) |
Patient/parent global disease activity assessment (0–10) | 4 (2–6) |
Function (CHAQ) (0–3) | 0.563 (0–1) |
Patient/parent pain assessment (0–10) | 4 (2–7) |
Abbreviations: IQR Interquartile range, HLA Human leukocyte antigen, MRI Magnetic resonance imaging, ANA Antinuclear antibody, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, CHAQ Childhood Health Assessment Questionnaire
Denominators for clinical characteristics varied because of missing data: HLA-B27 status (n = 228), magnetic resonance imaging-defined sacroiliitis (n = 45), ANA (n = 209), CRP (n = 145), ESR (n = 203), physician global disease activity assessment (n = 126), JSpADA (n = 116), patient/parent global disease activity assessment (n = 102), CHAQ (n = 120), patient/parent pain assessment (n = 129), cJADAS (JADAS3–10) (n = 86)